1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. Financials
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-08-09 am EDT
14.78 HKD   +2.07%
07/13China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System
CI
07/13Chinese Regulator Approves Venus Medtech's Valve Replacement System
MT
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 13 55528 14110 5615 567--
Enterprise Value (EV)2 11 28825 4227 6113 0243 4283 694
P/E ratio -27,5x-148x-28,4x-20,3x-28,2x-76,6x
Yield ------
Capitalization / Revenue 58,1x102x25,4x8,65x5,46x3,70x
EV / Revenue 48,4x92,1x18,3x4,70x3,36x2,45x
EV / EBITDA -37,7x-180x-33,5x-13,6x-20,9x64,8x
Price to Book 3,43x7,22x2,32x1,32x1,42x1,44x
Nbr of stocks (in thousands) 404 469422 969437 897437 897--
Reference price (CNY) 33,566,524,112,712,712,7
Announcement Date 03/27/202003/31/202103/31/2022---
1 HKD in Million
2 CNY in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 2332764166441 0201 506
EBITDA1 -299-141-227-223-16457,0
Operating profit (EBIT)1 -328-179-279-304-226-102
Operating Margin -141%-64,7%-67,0%-47,2%-22,2%-6,74%
Pre-Tax Profit (EBT)1 -382-186-378-314-231-96,1
Net income1 -381-182-374-308-228-96,2
Net margin -163%-65,9%-89,8%-47,8%-22,4%-6,39%
EPS2 -1,22-0,45-0,85-0,63-0,45-0,17
Dividend per Share2 ------
Announcement Date 03/27/202003/31/202103/31/2022---
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2
Net sales1 102174239177232348
EBITDA ------
Operating profit (EBIT)1 ---60,1-219-75,5-196
Operating Margin ---25,1%-124%-32,6%-56,2%
Pre-Tax Profit (EBT) ------
Net income ------
Net margin ------
EPS2 ---0,26-0,59-0,13-0,43
Dividend per Share ------
Announcement Date 08/28/202003/31/202108/31/202103/31/2022--
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 2 2672 7202 9502 5432 1401 874
Leverage (Debt / EBITDA) 7,58x19,3x13,0x11,4x13,1x-32,9x
Free Cash Flow1 -328-361-559-565-476-404
ROE (Net Profit / Equities) -21,8%-5,07%-8,94%-7,60%-6,98%-3,93%
Shareholders' equity1 1 7493 5904 1814 0493 2702 445
ROA (Net Profit / Asset) -16,2%-4,35%-7,93%-7,45%-5,95%-4,00%
Assets1 2 3524 1804 7144 1313 8332 404
Book Value Per Share2 9,769,2210,49,658,958,82
Cash Flow per Share2 -0,98-0,58-1,04-1,09-0,76-0,55
Capex1 24,5124102124138142
Capex / Sales 10,5%44,9%24,5%19,2%13,5%9,45%
Announcement Date 03/27/202003/31/202103/31/2022---
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Key data
Capitalization (HKD) 6 472 124 207
Capitalization (USD) 824 482 824
Net sales (CNY) 415 862 000
Net sales (USD) 61 584 551
Number of employees 905
Sales / Employee (CNY) 459 516
Sales / Employee (USD) 68 049
Free-Float 79,7%
Free-Float capitalization (HKD) 5 156 580 750
Free-Float capitalization (USD) 656 895 962
Avg. Exchange 20 sessions (CNY) 25 781 732
Avg. Exchange 20 sessions (USD) 3 817 989
Average Daily Capital Traded 0,40%
EPS & Dividend